Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2000-05-05
2002-07-02
Shah, Mukund J. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S250000, C514S233500, C514S253080, C514S312000, C540S562000, C544S128000, C544S344000, C544S363000, C546S156000, C206S570000
Reexamination Certificate
active
06413956
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention relates to 4-oxo-quinoline-3-carboxamides and more specifically to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABA
A
receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. This invention also relates to the use of these imidazoloisoquinoline compounds in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABA
A
receptors in tissue sections.
2. Description of the Related Art
The GABA
A
receptor superfamily represents one of the classes of receptors through which the major inhibitory neurotransmitter, &ggr;-aminobutyric acid, or GABA, acts. Widely, although unequally, distributed through the mammalian brain, GABA mediates many of its actions through a complex of proteins called the GABA
A
receptor, which causes alteration in chloride conductance and membrane polarization.
A number of cDNAs for GABA
A
receptor subunits have been characterized. To date at least 6&agr;, 3&bgr;, 3&ggr;, 1&egr;, 1&dgr; and 2&rgr; subunits have been identified. It is generally accepted that native GABA
A
receptors are typically composed of 2&agr;, 2&bgr;, and 1&ggr; subunits (Pritchett & Seeburg
Science
1989; 245:1389-1392 and Knight et. al.,
Recept. Channels
1998; 6:1-18). Evidence such as message distribution, genome localization and biochemical study results suggest that the major naturally occurring receptor combinations are &agr;
1
&bgr;
2
&ggr;
2
, &agr;
2
&bgr;
3
&ggr;
2
, &agr;
3
&bgr;
3
&ggr;
2
, and &agr;
5
&bgr;
3
&ggr;
2
(Mohler et. al. Neuroch. Res. 1995; 20(5): 631-636).
Benzodiazepines exert their pharmacological actions by interacting with the benzodiazepine binding sites associated with the GABA
A
receptor. In addition to the benzodiazepine site, the GABA
A
receptor contains sites of interaction for several other classes of drugs. These include a steroid binding site, a picrotoxin site, and the barbiturate site. The benzodiazepine site of the GABA
A
receptor is a distinct site on the receptor complex that does not overlap with the site of interaction for GABA or for other classes of drugs that bind to the receptor (see, e.g., Cooper, et al., The Biochemical Basis of Neuropharmacology, 6
th
ed., 1991, pp. 145-148, Oxford University Press, New York). Early electrophysiological studies indicated that a major action of the benzodiazepines was enhancement of GABAergic inhibition. Compounds that selectively bind to the benzodiazepine site and enhance the ability of GABA to open GABA
A
receptor channels are agonists of GABA receptors. Other compounds that interact with the same site but negatively modulate the action of GABA are called inverse agonists. Compounds belonging to a third class bind selectively to the benzodiazepine site and yet have little or no effect on GABA activity, but can block the action of GABA
A
receptor agonists or inverse agonists that act at this site. These compounds are referred to as antagonists.
The important allosteric modulatory effects of drugs acting at the benzodiazepine site were recognized early and the distribution of activities at different receptor subtypes has been an area of intense pharmacological discovery. Agonists that act at the benzodiazepine site are known to exhibit anxiolytic, sedative, and hypnotic effects, while compounds that act as inverse agonists at this site elicit anxiogenic, cognition enhancing, and proconvulsant effects. While benzodiazepines have a long history of pharmaceutical use as anxiolytics, these compounds often exhibit a number of unwanted side effects. These may include cognitive impairment, sedation, ataxia, potentiation of ethanol effects, and a tendency for tolerance and drug dependence.
GABA
A
selective ligands may also act to potentiate the effects of certain other CNS active compounds. For example, there is evidence that selective serotonin reuptake inhibitors (SSRIs) may show greater antidepressant activity when when used in combination with GABA
A
selective ligands than when used alone.
SUMMARY OF THE INVENTION
Disclosed are compounds, particularly 4-oxo-napthyridine-3-carboxamides, that bind to cell surface receptors. Compounds of the invention bind to GABA receptors, in particular these compounds possess affinity for the benzodiazepine site of GABA
A
receptors, including human GABA
A
receptors. Preferred are compounds that exhibit high selectivity for the benzodiazepine site of the GABA
A
receptor. These compounds are therefore considered to be of use in the treatment of a broad array of diseases or disorders in patients which are characterized by modulation of GABA
A
receptors.
Such diseases or disorders include, but are not limited to depression, anxiety, sleep disorders, cognitive disorders, low alertness, psychosis, obesity, pain, Parkinson's disease, Alzheimer's disease, neurodegenerative diseases, movement disorders, Down's syndrome, and benzodiazepine overdoses.
Thus, the invention provides compounds of Formula I (shown below), and pharmaceutical compositions comprising compounds of Formula I.
The invention further comprises methods of treating patients suffering from certain CNS disorders with an effective amount of a compound of the invention. The patient may be a human or other mammal. Treatment of humans, domesticated companion animals (pet) or livestock animals suffering from certain CNS disorders with an effective amount of a compound of the invention is encompassed by the invention.
In a separate aspect, the invention provides a method of potentiating the actions of other CNS active compounds. This method comprises administering an effective amount of a compound of the invention with another CNS active compound.
Additionally this invention relates to the use of the compounds of the invention as probes for the localization of GABA
A
receptors in tissue sections.
Accordingly, a broad aspect of the invention is directed to compounds of Formula I:
Accordingly, a broad embodiment of the invention is directed to compounds of Formula I:
or the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, R
2
and W are defined below.
DETAILED DESCRIPTION OF THE INVENTION
The invention provides compounds of Formula I:
or the pharmaceutically acceptable salts and solvates thereof, wherein:
R
1
and R
2
are the same or different and represent hydrogen, halogen, lower alkyl, lower alkoxy, lower alkoxyalkyl, or cycloalkyl or cycloalkyl alkoxy, where each cycloalkyl group has from 3-7 members, where up to two of the cycloalkyl members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy; and
W is hydrogen; or
W is cycloalkyl having from 3-7 members, where up to two of the members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy; or
W is lower alkyl optionally substituted with up to three groups selected from:
i) hydroxy, lower alkoxy, and halogen,
ii) cycloalkyl having from 3-7 members, where up to two of the members are optionally hetero atoms selected from oxygen and nitrogen, and where any member of the cycloalkyl group is optionally substituted with halogen, lower alkyl or lower alkoxy, and
iii) aryl or heteroaryl optionally mono-, di-, or tri-substituted with:
a) halogen, hydroxy, lower alkyl, lower alkoxy, aminoalkyl, arylalkyl, heteroarylalkyl,
b) —NR
5
R
6
wherein R
5
and R
6
are the same or different and represent hydrogen, lower alkyl, or arylalkyl,
c) —(CH
2
)
n
O(CH
2
)
m
R
7
wherein n and m are independently 0, 1, 2 or 3 and R
7
is lower alkoxy, aryl, heteroaryl, amino, mono- or dialkylamino, or cycloalkyl
Albaugh Pamela A.
Cai Guolin
Currie Kevin S.
Rosewater Dan
McDonnell Koehnen Hulbert & Berghoff
McKenzie Thomas C
Neurogen Corporation
Shah Mukund J.
LandOfFree
Substituted 4-oxo-quinoline-3-carboxamides does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted 4-oxo-quinoline-3-carboxamides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted 4-oxo-quinoline-3-carboxamides will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2845626